LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

NCT06865885 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Drug Interactions
Primary Prevention
Cardiometabolic Syndrome
LDL-Cholersterol Lowering

Interventions

DRUG: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Sponsor

University of California, San Diego

Collaborators

[object Object]